First Time Loading...

Aerie Pharmaceuticals Inc
NASDAQ:AERI

Watchlist Manager
Aerie Pharmaceuticals Inc Logo
Aerie Pharmaceuticals Inc
NASDAQ:AERI
Watchlist
Price: 15.25 USD 0.07% Market Closed
Updated: May 4, 2024

Aerie Pharmaceuticals Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aerie Pharmaceuticals Inc
Revenue Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Aerie Pharmaceuticals Inc
NASDAQ:AERI
Revenue
$213.9m
CAGR 3-Years
53%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Revenue
$81.8B
CAGR 3-Years
-1%
CAGR 5-Years
0%
CAGR 10-Years
1%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$45.5B
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$58.5B
CAGR 3-Years
12%
CAGR 5-Years
7%
CAGR 10-Years
1%
Merck & Co Inc
NYSE:MRK
Revenue
$61.4B
CAGR 3-Years
14%
CAGR 5-Years
7%
CAGR 10-Years
3%
Eli Lilly and Co
NYSE:LLY
Revenue
$34.1B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
4%

Aerie Pharmaceuticals Inc
Revenue Breakdown

Breakdown by Geography
Aerie Pharmaceuticals Inc

Not Available

Breakdown by Segments
Aerie Pharmaceuticals Inc

Total Revenue: 194.1m USD
100%
Product Revenues, Net: 112.1m USD
57.8%
Licensing Revenues: 82m USD
42.2%

See Also

What is Aerie Pharmaceuticals Inc's Revenue?
Revenue
213.9m USD

Based on the financial report for Sep 30, 2022, Aerie Pharmaceuticals Inc's Revenue amounts to 213.9m USD.

What is Aerie Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 3Y
53%

Over the last year, the Revenue growth was 105%. The average annual Revenue growth rates for Aerie Pharmaceuticals Inc have been 53% over the past three years .